Autism and Associated Disorders: Cannabis as a Potential Therapy

Authors

Mariana Babayeva, Department of Biomedical and Pharmaceutical Sciences, Touro College of Pharmacy, New York, NY 10027, USA.
Haregewein Assefa, Department of Medicinal Chemistry, School of Pharmacy, College of Health Sciences, Mekelle University, 231 Tigray, Ethiopia.
Paramita Basu, Department of Biomedical and Pharmaceutical Sciences, Touro College of Pharmacy, New York, NY 10027, USA.
Zvi Loewy, Department of Biomedical and Pharmaceutical Sciences, Touro College of Pharmacy, New York, NY 10027, USA.

Author Type(s)

Faculty

Journal Title

Frontiers in Bioscience

First Page

1

Document Type

Article

Publication Date

1-13-2022

Department

Pathology, Microbiology and Immunology

Abstract

Autism spectrum disorder (ASD) is a group of disabilities with impairments in physical, verbal, and behavior areas. Regardless the growing frequency of autism, no medicine has been formed for the management of the ASD primary symptoms. The most frequently prescribed drugs are off-label. Therefore, there is necessity for an advance tactic for the treatment of autism. The endocannabinoid system has a central role in ruling emotion and social behaviors. Dysfunctions of the system donate to the behavioral deficits in autism. Therefore, the endocannabinoid system represents a potential target for the development of a novel autism therapy. Cannabis and associated compounds have produced substantial research attention as a capable therapy in neurobehavioral and neurological syndromes. In this review we examine the potential benefits of medical cannabis and related compounds in the treatment of ASD and concurrent disorders.

Recommended Citation

Babayeva, M., Assefa, H., Basu, P., & Loewy, Z. (2022). Autism and Associated Disorders: Cannabis as a Potential Therapy. Frontiers in Bioscience, 14 (1), 1. https://doi.org/10.31083/j.fbe1401001